CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical
Cardiac Biotech Solutions (OTCID: CBSC) has secured a $375,000 purchase order from Noventis Medical for 2,500 MyCardia AT Cardiac Event Monitoring devices at $150 per unit. The order will be fulfilled in two phases: 1,000 units immediately and 1,500 units within 90 days.
CBSC has also launched a recurring revenue model through a monthly rental program that includes device usage, AWS Cloud-based monitoring software, and patient applications. The revenue sharing structure allocates one-third of monthly rental fees to CBSC and two-thirds to distributor partners.
The company's MyCardia AT platform combines wearable technology with cloud connectivity and mobile applications, with regulatory clearances in the US and pending approvals in Canada and China.
Cardiac Biotech Solutions (OTCID: CBSC) ha ottenuto un ordine di acquisto da 375.000 $ da Noventis Medical per 2.500 dispositivi MyCardia AT per il monitoraggio degli eventi cardiaci, a 150 $ l’uno. La consegna è prevista in due fasi: 1.000 unità subito e 1.500 unità entro 90 giorni.
CBSC ha inoltre introdotto un modello di ricavi ricorrenti con un programma di noleggio mensile che comprende l’utilizzo del dispositivo, il software di monitoraggio basato su AWS Cloud e le app per i pazienti. La ripartizione dei ricavi assegna un terzo delle quote di noleggio mensili a CBSC e i restanti due terzi ai distributori partner.
La piattaforma MyCardia AT integra tecnologia indossabile, connettività cloud e applicazioni mobili; dispone di approvazioni regolatorie negli Stati Uniti e attende autorizzazioni in Canada e Cina.
Cardiac Biotech Solutions (OTCID: CBSC) ha asegurado una orden de compra de 375.000 $ por parte de Noventis Medical para 2.500 dispositivos MyCardia AT de monitorización cardíaca, a 150 $ por unidad. El pedido se entregará en dos fases: 1.000 unidades de inmediato y 1.500 dentro de 90 días.
CBSC también ha lanzado un modelo de ingresos recurrentes mediante un programa de alquiler mensual que incluye el uso del dispositivo, el software de monitorización en la nube de AWS y las aplicaciones para pacientes. La estructura de reparto de ingresos asigna un tercio de las tarifas mensuales de alquiler a CBSC y los otros dos tercios a los distribuidores socios.
La plataforma MyCardia AT combina tecnología wearable con conectividad en la nube y aplicaciones móviles, cuenta con autorizaciones regulatorias en EE. UU. y tiene aprobaciones pendientes en Canadá y China.
Cardiac Biotech Solutions (OTCID: CBSC)는 Noventis Medical로부터 심장 이벤트 모니터링 기기 MyCardia AT 2,500대에 대한 375,000달러 주문을 확보했으며, 단가 150달러입니다. 주문은 두 차례로 이행되며: 즉시 1,000대, 90일 이내에 1,500대가 공급됩니다.
CBSC는 기기 사용, AWS 클라우드 기반 모니터링 소프트웨어 및 환자용 애플리케이션을 포함한 월별 렌탈 프로그램을 통해 반복 수익 모델도 도입했습니다. 수익 배분 구조는 월 렌탈료의 1/3을 CBSC가, 나머지 2/3를 유통 파트너가 받도록 되어 있습니다.
MyCardia AT 플랫폼은 웨어러블 기술과 클라우드 연결, 모바일 애플리케이션을 결합했으며, 미국에서 규제 승인을 받았고 캐나다와 중국에서는 승인 대기 중입니다.
Cardiac Biotech Solutions (OTCID: CBSC) a obtenu un bon de commande de 375 000 $ de Noventis Medical pour 2 500 appareils MyCardia AT de surveillance des événements cardiaques, au prix de 150 $ l’unité. La commande sera exécutée en deux phases : 1 000 unités immédiatement et 1 500 unités dans un délai de 90 jours.
CBSC a également lancé un modèle de revenus récurrents via un programme de location mensuelle incluant l’utilisation de l’appareil, le logiciel de surveillance sur AWS Cloud et les applications patients. La répartition des revenus attribue un tiers des loyers mensuels à CBSC et les deux tiers aux distributeurs partenaires.
La plateforme MyCardia AT combine la technologie portable, la connectivité cloud et les applications mobiles ; elle dispose d’autorisations réglementaires aux États-Unis et attend des approbations au Canada et en Chine.
Cardiac Biotech Solutions (OTCID: CBSC) hat einen Bestellauftrag über 375.000 $ von Noventis Medical für 2.500 MyCardia AT Herzereignis-Überwachungsgeräte im Preis von 150 $ pro Stück erhalten. Die Lieferung erfolgt in zwei Teilen: 1.000 Einheiten sofort und 1.500 Einheiten innerhalb von 90 Tagen.
CBSC hat zudem ein wiederkehrendes Erlösmodell eingeführt: ein monatliches Mietprogramm, das die Gerätenutzung, eine AWS-Cloud-basierte Überwachungssoftware und Patienten-Apps umfasst. Die Umsatzaufteilung sieht ein Drittel der monatlichen Mietgebühren für CBSC und zwei Drittel für Vertriebspartner vor.
Die MyCardia AT-Plattform kombiniert Wearable-Technologie mit Cloud-Konnektivität und mobilen Apps; regulatorische Freigaben liegen in den USA vor und Genehmigungen in Kanada und China stehen noch aus.
- Secured significant $375,000 purchase order for 2,500 MyCardia AT devices
- Implemented new recurring revenue model through monthly rental program
- Established revenue sharing partnership with distributors
- Expanding global presence with US regulatory clearance and pending approvals in Canada and China
- Revenue share limited to one-third of monthly rental fees
- Delivery of majority of units (1,500) delayed up to 90 days
LAS VEGAS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the receipt of an initial purchase order from Noventis Medical, its exclusive Central America distribution partner, for the supply of 2,500 MyCardia AT Cardiac Event Monitoring devices. The total order value is
Under the terms of the agreement, 1,000 devices will be shipped immediately upon completion of production, with the remaining 1,500 units to be delivered within 90 days.
“This purchase order not only reinforces market demand for the MyCardia AT but also marks the beginning of a sustainable, long-term revenue model,” said Charles Martin, Chief Executive Officer of CBSC. “By combining device sales with recurring software-driven rental fees, we believe that we are positioned to deliver consistent value for both our healthcare partners and our shareholders.”
In addition to upfront device sales, CBSC has implemented a recurring monthly rental program to generate ongoing revenue from devices once deployed in hospitals and healthcare facilities. This program covers the use of each device, the AWS Cloud-based monitoring software, and patient-facing smartphone applications.
Revenue from the monthly rental program is shared between CBSC and its distributor partners, with CBSC receiving one-third of the monthly fee and the distributor retaining the balance. Pricing varies by country, reflecting regional healthcare economics and reimbursement practices.
The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and additional submissions progressing in Canada and China, this newest international agreement represents another significant milestone in CBSC’s mission to deliver state-of-the-art cardiac monitoring solutions worldwide.
About Noventis Medical
Noventis Medical, headquartered in Panama City, Panama, is a leading distributor of advanced medical technologies throughout Central America. The company specializes in introducing innovative healthcare solutions designed to improve patient outcomes across hospitals and clinical networks.
About Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
FAQ
What is the value of CBSC's new purchase order from Noventis Medical?
How does CBSC's new recurring revenue program work?
What is the delivery schedule for CBSC's Noventis Medical order?
Where has CBSC received regulatory clearance for MyCardia AT?
What features does CBSC's MyCardia AT platform include?
